The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.
ChiaSKSpeersCHD'yachkovaY. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer2007; 110(5):973–9.
2.
LaunchburyAPHabboubiN. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev1993; 19(3):197–228.
3.
SmithLACorneliusVRPlummerCJLevittGVerrillMCanneyPJonesA. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer2010; 10:337.
4.
HuangKJ. Liposome pharmacokinetics. In: OstroM. J. (ed.). Liposomes from Biophysics to Therapeutics, pp. 109–156. New York. Marcel Dekker, 1987.
5.
RobertNJVogelCLHendersonIC. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol2004; 31(S):106–46.
6.
EwerMSMartinFJHendersonCShapiroCLBenjaminRSGabizonAA. Cardiac safety of liposomal anthracyclines. Semin Oncol2004; 31(S):161–81.
7.
RahmanAMYusufSWEwerMS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine2007; 2(4):567–83.
8.
ValeroVBuzdarAUTheriaultRL. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol1999; 17(5): 1425–34.
9.
ShapiroCLErvinTWellesLAzarniaNKeatingJHayesDF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol1999; 17(5):1435–41.
10.
BatistGBartonJChaikinPSwensonCWellesL. NPLD (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother2002; 3(12):1739–51.
11.
SwensonCEBolcsakLEBatistG. Pharmacokinetics of doxorubicin administered i.v. as NPLD (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs2003; 14(3):239–46.
12.
VenturiniMBighinCPuglisiF. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast2010; 19(5):333–8.
13.
RosatiMSRaimondiCBaciarelloG. Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II). Ann Oncol2011; 22(2):315–20.
14.
BatistGRamakrishnanGRaoCS. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol2001; 19(5):1444–54.
15.
HarrisLBatistGBeltRRoviraDNavariRAzarniaNWellesLWinerE; TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer2002; 94(1):25–36.
16.
ChanSDavidsonNJuozaityteEErdkampFPluzanskaAAzarniaNLeeLW. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol2004; 15(10): 1527–34.
17.
BatistGHarrisLAzarniaNLeeLWDaza-RamirezP. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs2006; 17(5):587–95.
18.
MillerKWangMGralowJ. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med2007; 357:2666–76.
19.
MilesDWChanADirixLY. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239–47.
20.
GradisharWJTjulandinSDavidsonNShawHDesaiNBharPHawkinsMO'ShaughnessyJ. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794–803.
21.
WuDGambhirSS. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. Clin Breast Cancer2003; 4(S):S55–63.
22.
Dose SchwarzJBaderMJenickeLHemmingerGJänickeFAvrilN. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med2005; 46(7): 1144–50.
23.
TateishiUGamezCDawoodSYeungHWCristofanilliMMacapinlacHA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology2008; 247:189–96.
24.
ErdkampF. Phase III study of TLC D-99 (liposome encapsulated doxorubicin) plus cyclophosphamide vs epirubicin plus cyclophosphamide in patients with metastatic breast carcinoma. Proc ASCO1999; 18:121a (Abstr 459).
25.
MarthyM. Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison. Breast2001; 10(S):28–33.
26.
GiottaFLorussoVMaielloE. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. Ann Oncol. 2007; 18(S):vi66–9.
27.
LiviLMeattiniICardillo CdeL. Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis. Tumori2009; 95(4):422–6.
